Acute respiratory distress syndrome. Potential pharmacologic interventions.

[1]  G. W. Paul,et al.  Characteristics of pulmonary surfactant in adult respiratory distress syndrome associated with trauma and shock. , 2015, The American review of respiratory disease.

[2]  S. Lundin,et al.  Inhalation of nitric oxide in acute lung injury: results of a European multicentre study , 1999, Intensive Care Medicine.

[3]  L. Nelson,et al.  Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. , 1999, Critical care medicine.

[4]  M. Murray,et al.  Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. , 1999, Critical care medicine.

[5]  Y. Jammes,et al.  Inhaled nitric oxide and vasoconstrictors in acute respiratory distress syndrome. , 1999, American journal of respiratory and critical care medicine.

[6]  C. Finck,et al.  Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass. , 1999, Circulation.

[7]  M. Moss,et al.  Ethanol ingestion impairs alveolar epithelial glutathione homeostasis and function, and predisposes to endotoxin-mediated acute lung injury. , 1999, Chest.

[8]  G. Bernard,et al.  Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. , 1999, Critical care medicine.

[9]  J. Zimmerman,et al.  Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. , 1998, Critical care medicine.

[10]  Citations from the Literature , 1998 .

[11]  G. Meduri,et al.  Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. , 1998, JAMA.

[12]  L. Brochard,et al.  Corticosteroid therapy in acute respiratory distress syndrome: better late than never? , 1998, JAMA.

[13]  C. Hörmann,et al.  Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. , 1998, American journal of respiratory and critical care medicine.

[14]  R. Schumann,et al.  LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. , 1998, The Journal of clinical investigation.

[15]  M. Booke,et al.  Inhaled Prostaglandin E1 for Treatment of Acute Lung Injury in Severe Multiple Organ Failure , 1998, Anesthesia and analgesia.

[16]  D. Su,et al.  Limulus antilipopolysaccharide factor prevents mortality late in the course of endotoxemia. , 1998, The Journal of infectious diseases.

[17]  W. Sibbald,et al.  Polymyxin-dextran antiendotoxin pretreatment in an ovine model of normotensive sepsis. , 1997, Critical care medicine.

[18]  B. Giroir,et al.  Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis , 1997, The Lancet.

[19]  I. Sils,et al.  Effects of almitrine bismesylate in a microswine model of hypoxemic hypothermia. , 1997, Aviation, space, and environmental medicine.

[20]  R. McIntyre,et al.  Pentoxifylline treatment attenuates pulmonary vasomotor dysfunction in acute lung injury. , 1997, The Journal of surgical research.

[21]  P. Tobias,et al.  Lipopolysaccharide (LPS)-binding Proteins BPI and LBP Form Different Types of Complexes with LPS* , 1997, The Journal of Biological Chemistry.

[22]  G. Bernard,et al.  A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. , 1997, Chest.

[23]  N. Mayer,et al.  Effects of pentoxifylline on hemodynamics and oxygenation in septic and nonseptic patients. , 1997, Critical care medicine.

[24]  J. Davis,et al.  Recombinant human superoxide dismutase reduces lung injury caused by inhaled nitric oxide and hyperoxia. , 1997, The American journal of physiology.

[25]  N. Maekawa,et al.  ONO-5046, an Elastase Inhibitor, Attenuates Endotoxin-Induced Acute Lung Injury in Rabbits , 1997, Anesthesia and analgesia.

[26]  G. Bernard,et al.  The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. , 1997, The New England journal of medicine.

[27]  M. Haller,et al.  Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. , 1996, American journal of respiratory and critical care medicine.

[28]  J. E. Doran,et al.  Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia , 1996, The Journal of experimental medicine.

[29]  R. Ulevitch,et al.  Antibodies against CD14 protect primates from endotoxin-induced shock. , 1996, The Journal of clinical investigation.

[30]  C. T. Park,et al.  Plasma Lipopolysaccharide-binding Protein Is Found Associated with a Particle Containing Apolipoprotein A-I, Phospholipid, and Factor H-related Proteins* , 1996, The Journal of Biological Chemistry.

[31]  W. Zapol,et al.  New approaches to acute lung injury. , 1996, British journal of anaesthesia.

[32]  R. S. St John,et al.  Immunotherapy for sepsis. , 1996, Clinics in chest medicine.

[33]  K. Takatsuki,et al.  Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes. , 1996, Critical Care Medicine.

[34]  P. Shek,et al.  TREATMENT OF LPS‐INDUCED TISSUE INJURY: ROLE OF LIPOSOMAL ANTIOXIDANTS , 1996, Shock.

[35]  J. Odeberg,et al.  The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. , 1996, European journal of biochemistry.

[36]  M. Fink,et al.  ROLE OF OXIDANT STRESS IN THE ADULT RESPIRATORY DISTRESS SYNDROME: EVALUATION OF A NOVEL ANTIOXIDANT STRATEGY IN A PORCINE MODEL OF ENDOTOXIN‐INDUCED ACUTE LUNG INJURY , 1996, Shock.

[37]  A. Anzueto,et al.  Aerosolized Surfactant in Adults with Sepsis-Induced Acute Respiratory Distress Syndrome , 1996 .

[38]  W. Seeger,et al.  Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. , 1996, American journal of respiratory and critical care medicine.

[39]  M. Pabst,et al.  An analogue of lipid A and LPS from Rhodobacter sphaeroides inhibits neutrophil responses to LPS by blocking receptor recognition of LPS and by depleting LPS‐binding protein in plasma , 1995, Journal of leukocyte biology.

[40]  M. Tönz,et al.  Acute lung injury during cardiopulmonary bypass. Are the neutrophils responsible? , 1995, Chest.

[41]  F. Stentz,et al.  Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. , 1995, Chest.

[42]  F. Stentz,et al.  Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. , 1995, Chest.

[43]  M. Boermeester,et al.  Effect of hypertriglyceridemia on endotoxin responsiveness in humans , 1995, Infection and immunity.

[44]  L. Frazee,et al.  Ketoconazole to Prevent Acute Respiratory Distress Syndrome in Critically Iii Patients , 1995, The Annals of pharmacotherapy.

[45]  A. Eerenberg,et al.  Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. , 1995, The Journal of infectious diseases.

[46]  S. Bucklin,et al.  Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia , 1995, Antimicrobial agents and chemotherapy.

[47]  J. Gegner,et al.  Lipopolysaccharide Binding Protein-mediated Complexation of Lipopolysaccharide with Soluble CD14 (*) , 1995, The Journal of Biological Chemistry.

[48]  K. Feingold,et al.  Role for circulating lipoproteins in protection from endotoxin toxicity , 1995, Infection and immunity.

[49]  A. Robidoux,et al.  E5531, a pure endotoxin antagonist of high potency. , 1995, Science.

[50]  J. Beckman,et al.  Evidence for in vivo peroxynitrite production in human acute lung injury. , 1995, American journal of respiratory and critical care medicine.

[51]  R. Landmann,et al.  Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock. , 1995, The Journal of infectious diseases.

[52]  M. Wurfel,et al.  Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS , 1994, The Journal of experimental medicine.

[53]  B. Hammer,et al.  Effect of a recombinant endotoxin‐neutralizing protein on endotoxin shock in rabbits , 1994, Critical care medicine.

[54]  L. Moldawer,et al.  Anti‐Endotoxin Therapy in Primate Bacteremia with HA‐1A and BPI , 1994, Annals of surgery.

[55]  G. Bernard.  Acute Respiratory Distress Syndrome: Potential Therapeutic Interventions , 1994 .

[56]  S. Opal,et al.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. , 1994, JAMA.

[57]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[58]  B. Winkelmann,et al.  Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. , 1994, Chest.

[59]  H. Winer-Muram,et al.  Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS. Patterns of response and predictors of outcome. , 1994, Chest.

[60]  T. Hurst,et al.  Neutrophil-mediated acute lung injury after extracorporeal perfusion. , 1994, The Journal of thoracic and cardiovascular surgery.

[61]  C. Natanson,et al.  Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis , 1994, Annals of Internal Medicine.

[62]  T. Tani,et al.  Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. , 1994, American journal of surgery.

[63]  M. Hallman,et al.  Successful treatment of ARDS with two doses of synthetic surfactant. , 1994, Chest.

[64]  B. Freeman.  Free radical chemistry of nitric oxide. Looking at the dark side. , 1994, Chest.

[65]  Jonathan Cohen,et al.  Pathogenesis and potential strategies for prevention and treatment of septic shock: an update. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[66]  M. Wurfel,et al.  Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14 , 1994, The Journal of experimental medicine.

[67]  S. Opal,et al.  Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open‐label, placebocontrolled multicenter trial , 1994, Critical care medicine.

[68]  M. Yu,et al.  A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome , 1993, Critical care medicine.

[69]  W. Seeger,et al.  Aerosolised prostacyclin in adult respiratory distress syndrome , 1993, The Lancet.

[70]  R. Bone,et al.  Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.

[71]  G. Sigurdsson,et al.  Effects of pentoxifylline on hemodynamics, gas exchange and multiple organ platelet sequestration in experimental endotoxic shock , 1993, Acta anaesthesiologica Scandinavica.

[72]  R. Carlson,et al.  Cecal ligation and puncture is associated with pulmonary injury in the rat: role of cyclooxygenase pathway products. , 1993, Prostaglandins.

[73]  P. Montravers,et al.  Pilot study of cardiopulmonary risk from pentoxifylline in adult respiratory distress syndrome. , 1993, Chest.

[74]  A. Jobe,et al.  Pulmonary surfactant therapy. , 1993, The New England journal of medicine.

[75]  G. Hedenstierna,et al.  Inhaled Nitric Oxide Selectively Reverses Human Hypoxic Pulmonary Vasoconstriction without Causing Systemic Vasodilation , 1993, Anesthesiology.

[76]  J. Vincent,et al.  Influence of an anti‐tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis , 1993, Critical care medicine.

[77]  R. Rossaint,et al.  Inhaled nitric oxide for the adult respiratory distress syndrome. , 1993, New England Journal of Medicine.

[78]  J. Vincent,et al.  Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. , 1993, Chest.

[79]  S Westaby,et al.  Inflammatory response to cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[80]  T. Evans,et al.  Chronic adult respiratory distress syndrome--a role for corticosteroids? , 1992, Critical care medicine.

[81]  A. Fowler,et al.  The neutrophil respiratory burst and tissue injury in septic acute lung injury: the effect of cyclooxygenase inhibition in swine. , 1992, Surgery.

[82]  H. S. Warren,et al.  Binding and neutralization of endotoxin by Limulus antilipopolysaccharide factor , 1992, Infection and immunity.

[83]  S. Suter,et al.  High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. , 1992, The American review of respiratory disease.

[84]  M. Weil,et al.  Monophosphoryl lipid A attenuates the effects of endotoxic shock in pigs. , 1992, The Journal of laboratory and clinical medicine.

[85]  C. Thompson,et al.  Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock. , 1992, The Journal of infectious diseases.

[86]  G. Bernard,et al.  The role of cyclooxygenase products in lung injury induced by tumor necrosis factor in sheep. , 1992, The American review of respiratory disease.

[87]  J. Herbert,et al.  Biochemical and pharmacological activities of SR 26831, a potent and selective elastase inhibitor. , 1992, The Journal of pharmacology and experimental therapeutics.

[88]  C. R. Reed,et al.  Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. , 1991, The Journal of clinical investigation.

[89]  Y. Phillips,et al.  Urinary desmosine excretion as a marker of lung injury in the adult respiratory distress syndrome. , 1991, Chest.

[90]  A. P. Timerman,et al.  Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. , 1991, Chest.

[91]  R. Wunderink,et al.  Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. , 1991, Chest.

[92]  H. Polk,et al.  Endotoxin filtration and immune stimulation improve survival from gram-negative sepsis. , 1991, Surgery.

[93]  G. Bernard,et al.  N-acetylcysteine in experimental and clinical acute lung injury. , 1991, The American journal of medicine.

[94]  M. A. Martin,et al.  A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. , 1991, JAMA.

[95]  A. Fowler,et al.  Tumor necrosis factor levels in serum and bronchoalveolar lavage fluid of patients with the adult respiratory distress syndrome. , 1991, The American review of respiratory disease.

[96]  C. Sprung,et al.  The HA-1A monoclonal antibody for gram-negative sepsis. , 1991, The New England journal of medicine.

[97]  F. Jardin,et al.  Comparison of the effects of intravenous almitrine and positive end-expiratory pressure on pulmonary gas exchange in adult respiratory distress syndrome. , 1991, The European respiratory journal.

[98]  B. Robertson,et al.  Inactivation of Exogenous Surfactant by Pulmonary Edema Fluid , 1991, Pediatric Research.

[99]  M. Avery,et al.  Surfactant-replacement therapy. , 1991, The New England journal of medicine.

[100]  J. Ansquer,et al.  Two years treatment with almitrine bismesylate in patients with hypoxic chronic obstructive airways disease. , 1991, The European respiratory journal.

[101]  M. Schaller,et al.  Plasma levels of tumor necrosis factor in the adult respiratory distress syndrome. , 1991, The American review of respiratory disease.

[102]  T. Raffin,et al.  Early post-treatment with pentoxifylline or dibutyryl cAMP attenuates Escherichia coli-induced acute lung injury in guinea pigs. , 1991, The American review of respiratory disease.

[103]  Rinaldo Je,et al.  Mechanisms and mediators of the adult respiratory distress syndrome. , 1990 .

[104]  D. Richman,et al.  A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. , 1990, The New England journal of medicine.

[105]  L. La Voie,et al.  Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. , 1990, The New England journal of medicine.

[106]  G. Bernard,et al.  Studies of an antiendotoxin antibody in preventing the physiologic changes of endotoxemia in awake sheep. , 1990, The American review of respiratory disease.

[107]  R. Ulevitch,et al.  Structure and function of lipopolysaccharide binding protein. , 1990, Science.

[108]  R. Ulevitch,et al.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. , 1990, Science.

[109]  J. Hoidal,et al.  Sulfated polysaccharides prevent human leukocyte elastase-induced acute lung injury and emphysema in hamsters. , 1990, The American review of respiratory disease.

[110]  J. Montaner,et al.  Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS) , 1990, Annals of internal medicine.

[111]  P. Meier,et al.  Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. , 1990, The New England journal of medicine.

[112]  Schade Uf.  Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. , 1990 .

[113]  P. Radermacher,et al.  Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: effects on pulmonary capillary pressure and ventilation-perfusion distributions. , 1990, Anesthesiology.

[114]  A. Fowler,et al.  Immunoreactive interleukin-1 in bronchoalveolar lavage fluid of high-risk patients and patients with the adult respiratory distress syndrome. , 1989, Experimental lung research.

[115]  M. Lamy,et al.  Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. , 1989, Critical care medicine.

[116]  J. Heffner,et al.  Pulmonary strategies of antioxidant defense. , 1989, The American review of respiratory disease.

[117]  R. Bone,et al.  Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome , 1989 .

[118]  H. Foda,et al.  Pharmacologic modulation of lung injury. , 1989, The American review of respiratory disease.

[119]  W. Buurman,et al.  Plasma tumor necrosis factor and mortality in critically ill septic patients. , 1989, Critical care medicine.

[120]  S. Weiss.  Tissue destruction by neutrophils. , 1989, The New England journal of medicine.

[121]  M. Wewers,et al.  Alveolar fluid neutrophil elastase activity in the adult respiratory distress syndrome is complexed to alpha-2-macroglobulin. , 1988, The Journal of clinical investigation.

[122]  W. Sibbald,et al.  Ibuprofen reduces the progression of permeability edema in an animal model of hyperdynamic sepsis. , 1988, Journal of applied physiology.

[123]  J. Murray,et al.  Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. , 1988, The American review of respiratory disease.

[124]  S. Peters,et al.  The role of cyclooxygenase and lipoxygenase mediators in oxidant-induced lung injury. , 1988, The American review of respiratory disease.

[125]  J. Oates,et al.  Prostaglandin E2 attenuation of sheep lung responses to endotoxin. , 1988, Journal of applied physiology.

[126]  S. Moncada,et al.  Metabolism of Arachidonic Acid , 1988, Annals of the New York Academy of Sciences.

[127]  C. Sprung,et al.  High-dose corticosteroids in patients with the adult respiratory distress syndrome. , 1987, The New England journal of medicine.

[128]  D. Golenbock,et al.  Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin , 1987, Infection and immunity.

[129]  C. Feldman,et al.  'Low-dose' corticosteroid prophylaxis against fat embolism. , 1987, The Journal of trauma.

[130]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[131]  A. Reyes,et al.  Almitrine in acute respiratory failure. Effects on pulmonary gas exchange and circulation. , 1987, Chest.

[132]  G. Slotman,et al.  Ketoconazole prevents acute respiratory failure in critically ill surgical patients. , 1986, The Journal of trauma.

[133]  L. Carey,et al.  Amelioration of pulmonary pathophysiology of adult respiratory distress syndrome by sulindac, a cyclo-oxygenase inhibitor. , 1986, The Journal of trauma.

[134]  B. Meyrick,et al.  Endotoxin and lung injury. , 1986, The American review of respiratory disease.

[135]  M. Vassar,et al.  Prostaglandin E1 and Survival in Patients with the Adult Respiratory Distress Syndrome: A Prospective Trial , 1986, Annals of surgery.

[136]  P. Dorinsky,et al.  Lung neutrophils in the adult respiratory distress syndrome. Clinical and pathophysiologic significance. , 1986, The American review of respiratory disease.

[137]  R. Simon,et al.  OXIDANT ACTIVITY IN EXPIRED BREATH OF PATIENTS WITH ADULT RESPIRATORY DISTRESS SYNDROME , 1986, The Lancet.

[138]  B. Pennock.  Effects of Ibuprofen on Endotoxin‐lnduced Alveolitis: Biphasic Dose Response and Dissociation Between Inflammation and Hypoxemia , 1986, The American journal of the medical sciences.

[139]  J. Modig,et al.  Prophylactic and delayed treatment with indomethacin in a porcine model of early adult respiratory distress syndrome induced by endotoxaemia , 1986, Acta anaesthesiologica Scandinavica.

[140]  R. Colman,et al.  Neutrophil elastase-releasing factors in bronchoalveolar lavage from patients with adult respiratory distress syndrome. , 1985, The American review of respiratory disease.

[141]  R. Ulevitch,et al.  Control of lipopolysaccharide-high-density lipoprotein interactions by an acute-phase reactant in human serum , 1985, Infection and immunity.

[142]  L. Hudson,et al.  Causes of Mortality in Patients with the Adult Respiratory Distress Syndrome , 1985, The American review of respiratory disease.

[143]  S. Iwanaga,et al.  Isolation and biological activities of limulus anticoagulant (anti-LPS factor) which interacts with lipopolysaccharide (LPS). , 1985, Journal of biochemistry.

[144]  R. Maier,et al.  Idiopathic pulmonary fibrosis in adult respiratory distress syndrome. Diagnosis and treatment. , 1985, Archives of surgery.

[145]  H. Kaplan,et al.  Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[146]  W. Seeger,et al.  Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. , 1985, Journal of applied physiology.

[147]  C. Sprung,et al.  The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. , 1984, The New England journal of medicine.

[148]  Y. Ploysongsang,et al.  Fat embolism prophylaxis with corticosteroids. A prospective study in high-risk patients. , 1983, Annals of internal medicine.

[149]  R. Spragg,et al.  Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. , 1982, The Journal of clinical investigation.

[150]  P. Pepe,et al.  Clinical predictors of the adult respiratory distress syndrome. , 1982, American journal of surgery.

[151]  R. Spragg,et al.  Studies on the pathogenesis of the adult respiratory distress syndrome. , 1982, The Journal of clinical investigation.

[152]  K. Brigham,et al.  Methylprednisolone prevention of increased lung vascular permeability following endotoxemia in sheep. , 1981, The Journal of clinical investigation.

[153]  A. Fein,et al.  Elastolytic activity in pulmonary lavage fluid from patients with adult respiratory-distress syndrome. , 1981, The New England journal of medicine.

[154]  G. W. Paul,et al.  Abnormalities in lung elastic properties and surfactant function in adult respiratory distress syndrome. , 1979, Chest.

[155]  L. Hinshaw,et al.  Increased survival with methylprednisolone treatment in canine endotoxin shock. , 1978, The Journal of surgical research.

[156]  D. Morrison,et al.  Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. , 1976, Immunochemistry.

[157]  W. Schumer.  Steroids in the Treatment of Clinical Septic Shock , 1976, Annals of surgery.

[158]  S. Permutt,et al.  Aspiration pneumonia: experimental evaluation of albumin and steroid therapy. , 1976 .

[159]  Corrigan Jj,et al.  Endotoxin-induced intravascular coagulation: prevention with polymyxin B sulfate. , 1971 .

[160]  W. Zapol.  Nitric oxide inhalation in acute respiratory distress syndrome: it works, but can we prove it? , 1998, Critical care medicine.

[161]  S A Conrad,et al.  Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial. , 1996, Critical care medicine.

[162]  D. Rossignol,et al.  Anti-endotoxin activity of a novel synthetic lipid A analog. , 1995, Progress in clinical and biological research.

[163]  E. Rackow,et al.  Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial. , 1995, Critical care medicine.

[164]  G. Bernard,et al.  Immunological Therapy of Endotoxaemia: Anti-endotoxin Antibodies , 1995 .

[165]  J. Repine,et al.  Liposome-entrapped PGE1 posttreatment decreases IL-1 alpha-induced neutrophil accumulation and lung leak in rats. , 1994, Journal of applied physiology.

[166]  L. Hudson,et al.  Outcome from respiratory failure. , 1994, Critical care clinics.

[167]  P. Richman,et al.  Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. , 1994, Chest.

[168]  N. Martinet,et al.  In vitro effects of pentoxifylline on smooth muscle cell migration and blood monocyte production of chemotactic activity for smooth muscle cells: potential therapeutic benefit in the adult respiratory distress syndrome. , 1993, American journal of respiratory cell and molecular biology.

[169]  E. Rackow,et al.  Comparison of the induction of endotoxin tolerance in endotoxemia and peritonitis by monophosphoryl lipid A and lipopolysaccharide. , 1993, Circulatory shock.

[170]  K. Brigham,et al.  Respiratory Distress Syndromes: Molecules to Man , 1991 .

[171]  S. Ryan,et al.  Effects of activated polymorphonuclear leukocytes upon pulmonary surfactant in vitro. , 1991, American journal of respiratory cell and molecular biology.

[172]  J. Murray,et al.  Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. , 1990, The American review of respiratory disease.

[173]  R. Hooper,et al.  Established ARDS treated with a sustained course of adrenocortical steroids. , 1990, Chest.

[174]  B. Lindeque,et al.  Fat embolism and the fat embolism syndrome. A double-blind therapeutic study. , 1987, The Journal of bone and joint surgery. British volume.

[175]  J. Modig,et al.  High-dose methylprednisolone in a porcine model of ARDS induced by endotoxemia. , 1985, Acta chirurgica Scandinavica. Supplementum.

[176]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .

[177]  Thomas Cs,et al.  The role of adrenal corticosteroid therapy in Escherichia coli endotoxin shock. , 1968 .